Cost-Effectiveness of Pembrolizumab for The First-Line Treatment of Metastatic Non-Small Cell Lung Carcinoma in Portugal
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.196
https://www.valueinhealthjournal.com/article/S1098-3015(17)30530-2/fulltext
Title :
Cost-Effectiveness of Pembrolizumab for The First-Line Treatment of Metastatic Non-Small Cell Lung Carcinoma in Portugal
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30530-2&doi=10.1016/j.jval.2017.08.196
First page :
A432
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
175